<DOC>
	<DOCNO>NCT00705315</DOCNO>
	<brief_summary>This study evaluate efficacy toxicity docetaxel-epirubicin combination plus bevacizumab first line treatment patient metastatic HER2 negative breast cancer .</brief_summary>
	<brief_title>Docetaxel/Epirubicin/Bevacizumab First Line Therapy Metastatic HER2 Negative Breast Cancer</brief_title>
	<detailed_description>A phase II trial 142 patient demonstrated therapy docetaxel plus epirubicin highly active first-line therapy metastatic breast cancer , acceptable toxicity profile . Recently initial therapy metastatic breast cancer paclitaxel plus bevacizumab demonstrate prolonged progression-free survival , compare paclitaxel alone . This study evaluate efficacy toxicity docetaxel-epirubicin combination plus bevacizumab first line treatment patient metastatic HER2 negative breast cancer . Furthermore , efficacy combination therapy correlate presence circulate tumor cell ( CTCs ) population .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic breast adenocarcinoma No HER2 overexpression gene amplification No previous therapy metastatic breast cancer allow Age 1875 year At least 12 month interval since prior adjuvant therapy taxanes and/or anthracyclines Measurable disease define presence least one measurable lesion ( except bone metastasis , ascites pleural effusion ) Performance status ( WHO ) 02 Adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit , AST ALT &lt; 2.5 time upper normal limit absence demonstrable liver metastasis , &lt; 5 time UNL presence liver metastasis ) Adequate renal function ( serum creatinine &lt; 1.5 time upper normal limit Adequate bone marrow function ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) Written inform consent Active infection Brain metastases History significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) History stroke Anticoagulation therapy ( except low dose aspirin &lt; 325mg ) Other invasive malignancy except nonmelanoma skin cancer Psychiatric illness social situation would preclude study compliance Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>biological therapy</keyword>
</DOC>